NasdaqGM - Nasdaq Real Time Price USD
Harrow, Inc. (HROW)
26.27
-0.39
(-1.46%)
At close: 4:00:02 PM EDT
26.28
+0.01
+(0.04%)
After hours: 7:30:11 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 1,386,000 | 3 |
| Sales | 35,000 | 4 |
| Net Shares Purchased (Sold) | 1,351,000 | 7 |
| Total Insider Shares Held | 5.53M | -- |
| % Net Shares Purchased (Sold) | 32.30% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| BAUM MARK L Chief Executive Officer | -- | Direct | -- | Apr 3, 2025 |
| BOLL ANDREW R Chief Financial Officer | -- | Direct | -- | Apr 3, 2025 |
| SAHAREK JOHN P Chief Executive Officer | -- | Direct | -- | Apr 3, 2025 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Sale at price 29.64 per share. | Indirect | 148,200 | Mar 18, 2025 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Sale at price 30.01 per share. | Indirect | 150,055 | Mar 18, 2025 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Sale at price 28.05 per share. | Indirect | 140,250 | Feb 28, 2025 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Sale at price 35.59 per share. | Indirect | 711,814 | Jan 22, 2025 |
| SAHAREK JOHN P Officer | Conversion of Exercise of derivative security at price 7.37 per share. | Direct | 663,300 | Sep 11, 2024 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 9.97 per share. | Indirect | 199,400 | Apr 25, 2024 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.15 - 10.29 per share. | Indirect | 204,640 | Apr 24, 2024 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.56 per share. | Indirect | 310,390 | Apr 19, 2024 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 12.82 per share. | Indirect | 641,000 | Mar 28, 2024 |
| BAUM MARK L Chief Executive Officer | Purchase at price 11.59 per share. | Direct | 104,310 | Mar 22, 2024 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 9.65 per share. | Indirect | 488,290 | Mar 20, 2024 |
| SAHAREK JOHN P Officer | Conversion of Exercise of derivative security at price 8.75 per share. | Direct | 43,750 | Mar 1, 2024 |
| BAUM MARK L Chief Executive Officer | Conversion of Exercise of derivative security at price 10.67 per share. | Direct | 1,600,500 | Feb 20, 2024 |
| BOLL ANDREW R Chief Financial Officer | Conversion of Exercise of derivative security at price 10.67 per share. | Direct | 197,182 | Feb 20, 2024 |
| SAHAREK JOHN P Officer | Conversion of Exercise of derivative security at price 10.67 per share. | Direct | 454,713 | Feb 20, 2024 |
| BAUM MARK L Chief Executive Officer | Conversion of Exercise of derivative security at price 7.71 per share. | Direct | 118,734 | Feb 7, 2024 |
| BOLL ANDREW R Chief Financial Officer | Conversion of Exercise of derivative security at price 7.71 per share. | Direct | 57,054 | Feb 7, 2024 |
| BAUM MARK L Chief Executive Officer | Purchase at price 8.11 per share. | Direct | 60,825 | Nov 16, 2023 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 8.03 per share. | Indirect | 200,735 | Nov 15, 2023 |
| SAHAREK JOHN P Officer | Conversion of Exercise of derivative security at price 4.16 per share. | Direct | 83,200 | Nov 10, 2023 |
| OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 14.49 - 14.65 per share. | Indirect | 292,076 | Sep 20, 2023 |
| BAUM MARK L Chief Executive Officer | Purchase at price 17.05 per share. | Direct | 98,890 | Aug 14, 2023 |
| MAKARY MARTIN A. Director | Purchase at price 16.92 per share. | Direct | 338,400 | Aug 14, 2023 |
| BAUM MARK L Chief Executive Officer | -- | Direct | -- | Jul 18, 2023 |
| BOLL ANDREW R Chief Financial Officer | -- | Direct | -- | Jul 18, 2023 |
| SAHAREK JOHN P Officer | -- | Direct | -- | Jul 18, 2023 |
Related Tickers
ETON Eton Pharmaceuticals, Inc.
17.07
-1.61%
EOLS Evolus, Inc.
10.13
+1.50%
LNTH Lantheus Holdings, Inc.
78.95
-0.72%
AVDL Avadel Pharmaceuticals plc
9.03
-5.84%
COLL Collegium Pharmaceutical, Inc.
29.80
+0.81%
ANIP ANI Pharmaceuticals, Inc.
62.00
-0.48%
AQST Aquestive Therapeutics, Inc.
2.2900
-19.65%
ALVO Alvotech
10.56
+3.02%
CPH.TO Cipher Pharmaceuticals Inc.
12.78
-3.18%
AKBA Akebia Therapeutics, Inc.
2.4800
+2.06%